Synapse - Dean Bajorin

Results (663)

Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: A subgroup analysis of the phase 3 KEYNOTE-045 trial

Journal Article

Nishiyama, H.; Yamamoto, Y.; Sassa, N.; Nishimura, K.; Fujimoto, K.; Fukasawa, S.; Yokoyama, M.; Enokida, H.; Takahashi, K.; Tanaka, Y.; more...
International Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

"Primary" and "secondary" muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes

Correspondence

Pietzak, E. J.; Al-Ahmadie, H.; Walasek, A.; Bajorin, D. F.; Rosenberg, J. E.; Bochner, B. H.; Solit, D. B.; Iyer, G.
Translational Cancer Research (2019)

Fulltext@MSK | Save

Eligibility and radiologic assessment in adjuvant clinical trials in bladder cancer

Review

Apolo, A. B.; Milowsky, M. I.; Kim, L.; Inman, B. A.; Kamat, A. M.; Steinberg, G.; Bagheri, M.; Krishnasamy, V. P.; Marko, J.; Dinney, C. P.; more...
JAMA Oncology (2019)

Fulltext@MSK | Save

Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)

Meeting Abstract

Necchi, A.; Fradet, Y.; Bellmunt, J.; de Wit, R.; Lee, J. L.; Fong, L.; Vozelgang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)

Meeting Abstract

Pal, S. K.; Bajorin, D. F.; Hoffman-Censits, J. H.; Quinn, D. I.; Petrylak, D. P.; Galsky, M. D.; Vaishampayan, U. N.; De Giorgi, U.; Gupta, S.; Burris, H. A.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)

Meeting Abstract

de Wit, R.; Kulkarni, G. S.; Uchio, E.; Boormans, J. L.; Roumiguie, M.; Krieger, L. E. M.; Singer, E. A.; Bajorin, D. F.; Kamat, A. M.; Grivas, P.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy

Journal Article

Feuerstein, M. A.; Goldstein, L.; Reaves, B.; Sun, A.; Goltzman, M.; Morganstern, B. A.; Shabsigh, A.; Bajorin, D. F.; Rosenberg, J. E.; Donat, S. M.; more...
World Journal of Urology (2019)

Fulltext@MSK | Save

5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors

Meeting Abstract

Sonpavde, G.; Manitz, J.; Gao, C.; Hennessy, D.; Makari, D.; Niegisch, G.; Rosenberg, J. E.; Bajorin, D. F.; Grivas, P.; Apolo, A. B.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC): Updated response and survival results

Meeting Abstract

O'Donnell, P. H.; Balar, A. V.; Vuky, J.; Castellano, D. E.; Bellmunt, J.; Powles, T.; Bajorin, D. F.; Grivas, P.; Hahn, N. M.; Plimack, E. R.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI)

Meeting Abstract

Mota, J. M.; Teo, M. Y.; Whiting, K.; Ostrovnaya, I.; Li, H.; Lee, C. H.; Funt, S. A.; Callahan, M. K.; Iyer, G.; Bajorin, D. F.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save